These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 30743222)

  • 21. DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy.
    Eberlein U; Nowak C; Bluemel C; Buck AK; Werner RA; Scherthan H; Lassmann M
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1739-1749. PubMed ID: 26048612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oleanolic acid enhances the radiosensitivity of tumor cells under mimetic hypoxia through the reduction in intracellular GSH content and HIF-1α expression.
    Qi R; Jin W; Wang J; Yi Q; Yu M; Xu S; Jin W
    Oncol Rep; 2014 May; 31(5):2399-406. PubMed ID: 24604140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [
    Vallejo-Armenta P; Soto-Andonaegui J; Villanueva-Pérez RM; González-Díaz JI; Contreras-Contreras K; Bautista-Wong CG; Sandoval-Bonilla B; Nettel-Rueda B; Santos-Cuevas C; Ferro-Flores G
    Nucl Med Biol; 2021; 96-97():1-8. PubMed ID: 33640681
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Santos-Cuevas C; Davanzo J; Ferro-Flores G; García-Pérez FO; Ocampo-García B; Ignacio-Alvarez E; Gómez-Argumosa E; Pedraza-López M
    Nucl Med Biol; 2017 Sep; 52():1-6. PubMed ID: 28575794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods.
    Guerra Liberal FD; Tavares AA; Tavares JM
    Med Phys; 2014 Nov; 41(11):114101. PubMed ID: 25370676
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Ocampo-García B; Cruz-Nova P; Jiménez-Mancilla N; Luna-Gutiérrez M; Oros-Pantoja R; Lara-Almazán N; Pérez-Velasco D; Santos-Cuevas C; Ferro-Flores G
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and evaluation of Lys¹(α,γ-Folate)Lys³(¹⁷⁷Lu-DOTA)-Bombesin(1-14) as a potential theranostic radiopharmaceutical for breast cancer.
    Aranda-Lara L; Ferro-Flores G; Azorín-Vega E; Ramírez FM; Jiménez-Mancilla N; Ocampo-García B; Santos-Cuevas C; Isaac-Olivé K
    Appl Radiat Isot; 2016 Jan; 107():214-219. PubMed ID: 26545016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer.
    Behe M; Alt K; Deininger F; Bühler P; Wetterauer U; Weber WA; Elsässer-Beile U; Wolf P
    In Vivo; 2011; 25(1):55-9. PubMed ID: 21282735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
    Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
    Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific Cytotoxicity of Targeted
    Pankratov AA; Nemtsova ER; Plyutinskaya AD; Vorontsova MS; Chuvilin DY; Egorova BV; Kokov KV; Deev SM; Lebedenko EN; Proshkina GM; Shul'ga AA; Golovachenko VA; Shegai PV; Kaprin AD
    Bull Exp Biol Med; 2021 Sep; 171(5):627-632. PubMed ID: 34626281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation and preliminary biological evaluation of a 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia.
    Das T; Chakraborty S; Banerjee S; Mukherjee A; Samuel G; Sarma HD; Nair CK; Kagiya VT; Venkatesh M
    Bioorg Med Chem; 2004 Dec; 12(23):6077-84. PubMed ID: 15519153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of the phosphorylation of ATM contributes to radioresistance of glioma stem cells.
    Zhou W; Sun M; Li GH; Wu YZ; Wang Y; Jin F; Zhang YY; Yang L; Wang DL
    Oncol Rep; 2013 Oct; 30(4):1793-801. PubMed ID: 23846672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging.
    Satterlee AB; Yuan H; Huang L
    J Control Release; 2015 Nov; 217():170-82. PubMed ID: 26341695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Fendler WP; Rahbar K; Herrmann K; Kratochwil C; Eiber M
    J Nucl Med; 2017 Aug; 58(8):1196-1200. PubMed ID: 28663195
    [No Abstract]   [Full Text] [Related]  

  • 39. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells.
    Giladi M; Munster M; Schneiderman RS; Voloshin T; Porat Y; Blat R; Zielinska-Chomej K; Hååg P; Bomzon Z; Kirson ED; Weinberg U; Viktorsson K; Lewensohn R; Palti Y
    Radiat Oncol; 2017 Dec; 12(1):206. PubMed ID: 29284495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.